Skip to main content
SpringerLink
Log in

Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation

  • Brief Report
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

Abstract

Recombinant factor VIIa (rFVIIa, NovoSeven) has been registered for the treatment of bleeding episodes in patients with inherited or acquired hemophilia A or B with inhibitors. Furthermore, rFVIIa has been used successfully for the treatment of bleeding in patients with thrombocytopenia, and acquired and congenital platelet dysfunction. The definite spectrum of indications for rFVIIa has not yet been established. We describe a case of severe intra-abdominal bleeding 3 days after non-heart beating kidney transplantation in a patient with severe coronary artery disease in which rFVIIa (a single intravenous bolus injection 70 μg/kg bodyweight) was successfully used. No thrombotic complications occurred. This report demonstrates that rFVIIa might be safe and effective after recent renal transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hedner U (2001) Recombinant factor VIIa (Novoseven) as a hemostatic agent. Semin Hematol 38:43–47

    Article  CAS  PubMed  Google Scholar 

  2. Palestini M, Randone B, Bianchi G, Ponzio F, Carmellini M, Citterio F, Bretto P, Boggi U, Castagneto M, Cavallaro A (2000) Donor and recipient postoperative complications in living related kidney transplantation. A multicentric study. Minerva Chir 55:709–712

    CAS  PubMed  Google Scholar 

  3. Malyszko JS, Malyszko J, Mysliwiec M (1999) Tissue factor and tissue factor pathway inhibitor in kidney allograft recipients. Transplant Proc 31:2118–2120

    Article  CAS  PubMed  Google Scholar 

  4. Schmidt RH, Lenz T, Grone HJ, Geiger H, Scheuermann EH (1999) Haemolytic-uraemic syndrome after tacrolimus rescue therapy for cortisone-resistant rejection. Nephrol Dial Transplant 14:979–983

    Article  CAS  PubMed  Google Scholar 

  5. Burke GW, Ciancio G, Cirocco R, Markou M, Olson L, Contreras N, Roth D, Esquenazi V, Tzakis A, Miller J (1999) Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement. Transplantation 68:1336–1342

    Article  CAS  PubMed  Google Scholar 

  6. Finn WF (1999) FK506 nephrotoxicity. Ren Fail 21:319–329

    CAS  PubMed  Google Scholar 

  7. Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL, Igarashi T, Tarr PI (2002) Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 346:23–32

    CAS  PubMed  Google Scholar 

  8. Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, Hagenaars AJ, Melsen T, Slooff MJ, van der Meer J (2001) Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 71:402–405

    CAS  PubMed  Google Scholar 

  9. Nakamura K, Yoshimura N, Sano H, Kobayashi Y, Ushigome H, Oka T (1998) Role of tissue factor in ischemia-reperfusion injury: immunohistochemical assessment of tissue factor pathway inhibitor staining of the liver. Transplant Proc 30:3737–3739

    Article  CAS  PubMed  Google Scholar 

  10. Sanchez Bueno F, Hernandez Q, Ramirez P, Robles R, Acosta F, Rodriguez JM, Parrilla P (1999) Vascular complications in a series of 300 orthotopic liver transplants. Transplant Proc 31:2409–2410

    Google Scholar 

  11. Roberts HR (2001) Recombinant factor VIIa (Novoseven) and the safety of treatment. Semin Hematol 38[Suppl 12]:48–50

  12. Bajaj MS, Bajaj SP (1997) Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 78:471–477

    CAS  PubMed  Google Scholar 

  13. Golino P, Ragni M, Cirillo P, Scognamiglio A, Ravera A, Buono C, Guarino A, Piro O, Lambiase C, Botticella F, Ezban M, Condorelli M, Chiariello M (2000) Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits. Am J Physiol Heart Circ Physiol 278:H1507–1516

    CAS  PubMed  Google Scholar 

  14. Peerlinck K, Vermylen J (1999) Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor. Thromb Haemost 82:1775–1776

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Prof. Dr. J.P. van Hooff, Department of Nephrology, and Dr. E.C.M. van Pampus, Department of Hematology, University Hospital Maastricht, for their critical comments on the manuscript

Author information

Authors and Affiliations

  1. Department of Intensive Care, University Hospital Maastricht, P.O. Box 5800, 6202 AZ , Maastricht, The Netherlands

    S. E. M. J. Gielen-Wijffels, W. N. K. A. van Mook, S. van der Geest & G. Ramsay

  2. Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands

    W. N. K. A. van Mook & S. van der Geest

  3. Department of Surgery, University Hospital Maastricht, Maastricht, The Netherlands

    G. Ramsay

Authors
  1. S. E. M. J. Gielen-Wijffels
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. N. K. A. van Mook
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. van der Geest
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Ramsay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. E. M. J. Gielen-Wijffels.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gielen-Wijffels, S.E.M.J., van Mook, W.N.K.A., van der Geest, S. et al. Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation. Intensive Care Med 30, 1232–1234 (2004). https://doi.org/10.1007/s00134-004-2181-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-004-2181-0

Keywords

Search

Navigation